UNSPSC 51273002: Cyclomethycaine

This classification denotes an anesthetic agent with the molecular formula C22H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15E9I74NZ8. European Medicines Agency schedules cyclomethycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06855MIG. The term CYCLOMETHYCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3. ).

UNSPSC 51273002 Cyclomethycaine is a Commodity code that maps poorly to the recent state and local solicitations tagged under it. The source shows no recent opportunities for cyclomethycaine—a local anesthetic—but instead lists three unrelated pharmaceutical procurements: naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative direct-to-manufacturer program (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target cyclomethycaine specifically or anesthetic pharmaceutical products in general. The code exhibits a significant mismatch between its nominal scope and actual recent state and local procurement activity.

The three opportunities posted between January and June 2026 reflect broader pharmaceutical supply, cost management, and distribution concerns across state health and human services agencies and cooperative purchasing groups rather than demand for this specific commodity. Seminole County's IFB 60459723LAS (due July 26, 2023) addresses opioid-response purchasing; Texas HHS's RFI HHS0017013 (posted April 3, 2026) explores direct manufacturer contracts outside traditional pharmacy benefit manager channels; and Minnesota MMCAP's RFP S1070000015802 (due March 26, 2026) establishes multi-state cooperative pricing for generics and OTC stock. The code shows little relevant recent activity and does not support a credible business development signal for cyclomethycaine procurement at the state and local level.